[Development of purified HFRS bivalent vaccine].
OBJECTIVE
To develop the purified HFRS bivalent vaccine.


METHODS
LR1 (type I) and R22 (type II) of HFRS virus were cultured respectively in Vero cells. The viral suspensions were harvested, inactivated with beta-propiolactone, concentrated by ultra-filtration, purified by zone centrifugation, and desucrosed by column chromatography. The qualified vaccine bulks of type I and type II were mixed equally and absorbed with AI(OH)3 for preparation of 3 lots vaccines.


RESULTS
The 3 lots vaccines all passed examination carried out by ourselves and reexamination performed by National Institute for the Control of Pharmaceutical and Biological Products . One of 3 lots has been used in clinical trial.


CONCLUSIONS
It is practical to develop the purified HFRS bivalent vaccine by Vero cell culture.
Yang
Shi-long
SL
Lanzhou Institute of Biological Products, Lanzhou 730046, China. yangsl186@sohu.com
Dong
Guan-mu
GM
Li
Juan
J
An
Qi
Q
Sun
Xiao-dong
XD
Sun
Xiao-hui
XH
Li
Ping
P
D000818:Animals; D002522:Chlorocebus aethiops; D002986:Clinical Trials as Topic; D018063:Hantaan virus / Q000276:immunology*; D006801:Humans; D007114:Immunization; D011786:Quality Control; D014709:Vero Cells; D014765:Viral Vaccines / Q000276:immunology* / Q000302:isolation & purification*
D014765:Viral Vaccines